Abstract:The pan‐cancer analyses of bromodomain containing 9 (BRD9) provided a comprehensive perspective for the development of BRD9‐based targeted therapies for a variety of different cancers. BRD9 may affect cancer progression through different phosphorylation sites or N6‐methyladenosine site modifications. BRD9 could be used as a novel biomarker for diagnosis of multiple cancer types. Our functional study of BRD9 showed interaction with SMARCD1. Knockdown of BRD9 could inhibit the progression of lung and colon cancers through the Wnt/β‐catenin signalling pathway. Background Mutations in one or more genes responsible for encoding subunits within the SWItch/Sucrose Non‐Fermentable (SWI/SNF) chromatin‐remodelling complexes are found in approximately 25% of cancer patients. Bromodomain containing 9 (BRD9) is a more recently identified protein coding gene, which can encode SWI/SNF chromatin‐remodelling complexes subunits. Although initial evaluations of the potential of BRD9‐based targeted therapy have been explored in the clinical application of a small number of cancer types, more detailed study of the diagnostic and prognostic potential, as well as the detailed biological mechanism of BRD9 remains unreported. Methods We used various bioinformatics tools to generate a comprehensive, pan‐cancer analyses of BRD9 expression in multiple disease types described in The Cancer Genome Atlas (TCGA). Experimental validation was conducted in tissue microarrays and cell lines derived from lung and colon cancers. Results Our study revealed that BRD9 exhibited elevated expression in a wide range of tumours. Analysis of survival data and DNA methylation for BRD9 indicated distinct conclusions for multiple tumours. mRNA splicing and molecular binding were involved in the functional mechanism of BRD9. BRD9 may affect cancer progression through different phosphorylation sites or N6‐methyladenosine site modifications. BRD9 could potentially serve as a novel biomarker for diagnosing different cancer types, especially could accurately forecast the prognosis of melanoma patients receiving anti‐programmed cell death 1 immunotherapy. BRD9 has the potential to serve as a therapeutic target, when pairing with etoposide in patients with melanoma. The BRD9/SMARCD1 axis exhibited promising discriminative performance in forecasting the prognosis of patients afflicted with liver hepatocellular carcinoma (LIHC) and mesothelioma. Additionally, this axis appears to potentially influence the immune response in LIHC by regulating the programmed death‐ligand 1 immune checkpoint. For experimental validation, high expression levels of BRD9 were observed in tumour tissue samples from both lung and colon cancer patients. Knocking down BRD9 led to the inhibition of lung and colon cancer development, likely via the Wnt/β‐catenin signalling pathway. Conclusions These pan‐cancer study revealed the diagnostic and prognostic potential, along with the biological mechanism of BRD9 as a novel therapeutic target in human tumours.

Cloning and Functional Characterization of the Regulation Region of Human Brd7 Gene

Tumor suppressor bromodomain-containing protein 7 cooperates with Smads to promote transforming growth factor-β responses

BRD7 Suppresses Tumor Chemosensitivity to CHK1 Inhibitors by Inhibiting USP1-mediated Deubiquitination of CHK1

Molecular cloning and characterization of a novel human BTB domain-containing gene, , which is down-regulated in glioma

Growth Suppression of Nasopharyngeal Carcinoma Cell Through Transfection of BRD7 Gene

miR-141 is involved in BRD7-mediated cell proliferation and tumor formation through suppression of the PTEN/AKT pathway in nasopharyngeal carcinoma

Prognostic Relevance of BRD7 Expression in Colorectal Carcinoma

BRD7 Stabilizes P53 via Dephosphorylation of MDM2 to Inhibit Tumor Growth in Breast Cancer Harboring Wild-type P53

Solution structure of BRD7 bromodomain and its interaction with acetylated peptides from histone H3 and H4.

BRD4 As a Therapeutic Target for Nonfunctioning and Growth Hormone Pituitary Adenoma.

Effects of Bromodomain on Subcellular Localization of BRD7

Effect of Blocking BRCAA1 Gene with Sirna on Proliferation of MCF-7 Cells and Expression of Rb Gene

LARP7 is a BRCA1 Ubiquitinase Substrate and Regulates Genome Stability and Tumorigenesis

Interaction and Functional Research of BRD7 and Adaptor-Related Protein Complex 3δ Protein

Molecular Cloning of a Novel Gene Down-Regulated in Nasopharyngeal Carcinoma

Molecular cloning and promoter analysis of downregulated in adenoma (DRA)

Pan‐cancer analyses of bromodomain containing 9 as a novel therapeutic target reveals its diagnostic, prognostic potential and biological mechanism in human tumours

Inactivation of BRD7 results in impaired cognitive behavior and reduced synaptic plasticity of the medial prefrontal cortex

Characterization Of Dapk1 As A Novel Transcriptional Target Of Brms1

Targeting bromodomian-containing protein 8 (BRD8): An advanced tool to interrogate BRD8

BRD7 Promotes Cell Proliferation and Tumor Growth Through Stabilization of c-Myc in Colorectal Cancer